Solid Biosciences to Present at ASGCT 25th Annual Meeting and CureDuchenne 2022 FUTURES National Conference
May 17, 2022 08:00 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Announces Updated Corporate Strategy to Develop SGT-001 and SGT-003 Pipeline Programs for Patients with Duchenne Muscular Dystrophy
April 27, 2022 07:30 ET
|
Solid Biosciences Inc.
- IGNITE DMD functional and durability patient data support advancement of SGT-001; Program transitioning to a commercially scaled transient transfection-based manufacturing process - - Novel capsid...
Solid Biosciences Management to Host Call on April 27, 2022 to Discuss Updated Corporate Strategy and First Quarter 2022 Financial Results
April 25, 2022 08:00 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and 2-Year Efficacy and Safety Data from the Ongoing Phase I/II IGNITE DMD Clinical Trial of SGT-001
March 14, 2022 08:09 ET
|
Solid Biosciences Inc.
- 2-year data from first three patients in the high dose (2E14 vg/kg) cohort suggest sustained or improved motor function, pulmonary function and clinically validated patient-reported outcomes...
Solid Biosciences to Participate at the SVB Leerink 11th Annual Global Healthcare Conference
February 10, 2022 08:00 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Outlines its Strategic Priorities for 2022 and Announces Corporate Updates
January 10, 2022 08:00 ET
|
Solid Biosciences Inc.
- Continue to advance SGT-001 by dosing additional patients in IGNITE DMD - - Advance next-generation Duchenne gene therapy program (SGT-003) to IND submission; SGT-003 has demonstrated enhanced...
Solid Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference
January 06, 2022 08:00 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Reports Inducement Grant to New Senior Vice President, Human Resources
January 04, 2022 08:00 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Provides Third Quarter 2021 Business Update and Financial Results
November 03, 2021 07:05 ET
|
Solid Biosciences Inc.
- Continued focus on advancing SGT-001 includes additional patient dosings in IGNITE DMD expected to begin in Q4 2021 - - Continued progress with SGT-003; Solid’s next-generation Duchenne gene...
Pathway Development Consortium Releases Draft White Paper to Facilitate AAV Gene Therapy Development
November 02, 2021 07:30 ET
|
Solid Biosciences Inc.; The Pathway Development Consortium; REGENXBIO Inc.
- Draft white paper published today by the Pathway Development Consortium provides a framework for applying the accelerated approval pathway to AAV gene therapy development - - Pathway Development...